Commercial Executive Brings Over 20 Years of Strategic Healthcare and Sales Leadership to Accelerate Growth and Scale Market Access for Non-Invasive Cardiac Analysis Platform
CardioWise, Inc., a pioneer in non-invasive cardiac computed tomography (cCT) analysis software, has named Richard Roberts as Chief Executive Officer and Member of the Board of Directors.
Roberts joins CardioWise with more than two decades of commercial execution, sales, and marketing leadership in the medical device and healthcare technology sectors. A market-creating commercial executive, Roberts brings a strong track record of building high-performance commercial teams, driving product launches, scaling early-stage companies, and generating substantial shareholder value.
In his first statement as CEO, Richard Roberts shared: "CardioWise is delivering a game-changing solution to cardiac diagnostics by combining advanced AI algorithms with cardiac CT to give clinicians unprecedented precision in early heart disease detection. I am thrilled to join the team as CEO and Board Member at such a pivotal time in the company's trajectory. I look forward to leading our commercial operations, expanding strategic partnerships, and accelerating market adoption of our innovative imaging platform to improve patient outcomes globally."
Prior to joining CardioWise, Roberts served as President & Chief Operating Officer at Myocardial Solutions, Inc. His broad commercial background includes senior executive and sales leadership roles at industry-leading companies including Forest Pharmaceuticals, Cardiovascular Systems, Inc., and CHF Solutions, Inc. Throughout his career, Roberts has spearheaded market launches for emerging healthcare start-ups and led successful multi-series fundraising rounds.
"Richard’s deep industry knowledge, proven ability to scale commercial operations, and visionary leadership make him the ideal executive to guide CardioWise into its next growth phase," said Calvin Goforth of the CardioWise Board of Directors. "His track record in cardiovascular commercialization aligns perfectly with our vision to establish CardioWise's non-invasive heart analysis software as a primary standard in cardiac care."
CardioWise leverages proprietary artificial intelligence algorithms combined with non-invasive cardiac CT data to construct quantified 3D heart models. The company's FDA 510(k)-cleared analysis software, including its Stretch Quantifier for Endocardial Engraved Zones (SQuEEZ®) technology, seamlessly integrates into existing clinical workflows to aid physicians in the early, accurate diagnosis of heart disease.
About CardioWise
CardioWise, Inc. is a medical technology company focused on transforming cardiac diagnostics through advanced software solutions. By connecting non-invasive cardiac computed tomography (cCT) data with proprietary AI algorithms, CardioWise produces intuitive 3D image models of the human heart that augment clinical decision-making and enable early detection of cardiac risk. To learn more, visit cardiowiseinc.com
About VIC Tech
VIC's unique investment model sources innovation directly from universities nationwide, offering funding to form new start-up companies and advance these technologies. In addition to the initial capital, VIC provides its portfolio companies with business and scientific resources, including interim management, accounting, marketing, engineering support, and more. To learn more, vist victech.com